KRRO

Korro Bio, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise

90%

bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion

60%

bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss

50%

bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise

90%

bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion

60%

bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss

50%

bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise

90%

bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion

60%

bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss

50%

bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise

90%

bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion

60%

bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss

50%

bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise

90%

bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion

60%

bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss

50%

bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise

90%

bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion

60%

bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss

50%

bullishMay 7

Raised approximately $85 million through a PIPE and $5.1 million via ATM offering.

capital raise

90%

bullishMay 7

R&D expenses decreased by 34% YoY due to program termination and workforce reductions.

margin expansion

60%

bearishMay 7

Net loss per share widened to $1.69 as collaboration revenue dropped to zero.

earnings miss

50%

Filing History

10-QMay 7, 2026

Korro Bio is currently a binary bet on the viability of its OPERA RNA-editing platform, specifically the KRRO-121 program. The 10-Q reveals a company that has successfully bought itself time through aggressive cost-cutting and strategic capital raises, but has simultaneously narrowed its path to success. The transition from LNP to GalNAc-conjugated delivery across its pipeline is a critical technical pivot that must be validated in human trials to prove the platform's efficacy. Investors are now weighing a fortified balance sheet against a depleted pipeline. The core tension lies in whether the capital efficiency achieved in Q1 2026 is a sustainable strategic shift or a desperate measure to survive until the next clinical data point. The upcoming 2026 IND filing for KRRO-121 and the nomination of an AATD development candidate in Q2 2026 will be the definitive catalysts that determine if Korro is a leader in precision genetic medicine or a cautionary tale of platform failure.